Drugs / HGP1201
last change May 2016 re-read 2 minutes ago

HGP1201

Developed for
benign prostatic hyperplasia
Investigated by
Hanmi Pharmaceutical Company Limited

Trials 3 · a red edge is where a trial was stopped

2015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT02715401 Oct → Nov 2015 benign prostatic hyperplasia, erectile dysfunction Hanmi Pharmaceutical Company Limited Completed No outcome recorded
Phase 1 NCT02712411 Jul → Aug 2015 erectile dysfunction, prostate disorder Hanmi Pharmaceutical Company Limited Completed No outcome recorded
Phase 1 NCT02243319 Sep → Dec 2014 Hanmi Pharmaceutical Company Limited Completed No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT02667938 Comparator Mar 2015 → Jan 2016 benign prostatic hyperplasia Hanmi Pharmaceutical Company Limited Completed No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 4 sources stand behind the page.

FieldValueCited text
Known as HGP1201 ClinicalTrials.gov intervention name — accepted as the source's own label NCT02667938
3

NCT02243319

NCT02712411

NCT02715401